Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intra-Cellular Ther (NQ: ITCI ) 72.89 +0.64 (+0.89%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intra-Cellular Ther < Previous 1 2 3 4 5 Next > 8 Analysts Assess Intra-Cellular Therapies: What You Need To Know April 03, 2024 Via Benzinga Where Intra-Cellular Therapies Stands With Analysts February 23, 2024 Via Benzinga 3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition February 21, 2024 Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. Via InvestorPlace Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies January 18, 2024 Via Benzinga In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies January 02, 2024 Via Benzinga Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat Expert Ratings for Intra-Cellular Therapies December 11, 2023 Via Benzinga Intra-Cellular Therapies's Earnings: A Preview November 01, 2023 Via Benzinga What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies August 22, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session December 14, 2023 Via Benzinga Are These Biotechs Ready To Launch? December 09, 2023 Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... Via Talk Markets Analyst Expectations for Intra-Cellular Therapies's Future August 03, 2023 Via Benzinga Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data July 06, 2023 Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are... Via Benzinga Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know July 06, 2023 Via Benzinga Analyst Expectations for Intra-Cellular Therapies's Future June 22, 2023 Via Benzinga Analyst Expectations for Intra-Cellular Therapies's Future June 05, 2023 Via Benzinga Recap: Intra-Cellular Therapies Q1 Earnings May 04, 2023 Via Benzinga A Preview Of Intra-Cellular Therapies's Earnings May 03, 2023 Via Benzinga Analyst Ratings for Intra-Cellular Therapies March 29, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023 April 20, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session April 07, 2023 Via Benzinga Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday March 29, 2023 Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday. Via Benzinga Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features March 28, 2023 Via Benzinga Analyst Ratings for Intra-Cellular Therapies March 02, 2023 Via Benzinga Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 28, 2023 Gainers Via Benzinga Why Intra-Cellular Therapies Climbed Tuesday March 28, 2023 The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression. Via The Motley Fool Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted March 28, 2023 The company believes it may have the answer for patients with "mixed features." Via Investor's Business Daily 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 28, 2023 Via Benzinga Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode March 15, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... Via FinancialNewsMedia Exposures COVID-19 < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.